2Thorens B,Waeber G.Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM[J].Diabetes,1993,42(9):1219-1225.
3Wei Y,Mojsov S.Tissue-specific expression of the human receptor for glucagon-like peptide-I:brain,heart and pancreatic forms have the same deduced amino acid sequences[J].FEBS Lett,1995,358(3):219-224.
4Yamato E,Ikegami H,Takekawa K,et al.Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1) [J].Horm Metab Res,1997,29(2):56-59.
5Bunck MC,Diamant M,Corner A,et al.One-year treatment with exenatide improves beta-cell function,compared with insulin glargine,in metformin-treated type 2 diabetic patients:a randomized,controlled trial[J].Diabetes Care,2009,32(5):762-768.
6Vilsboll T,Brock B,Perrild H,et al.Liraglutide,a once-daily human GLP-1 analogue,improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus[J].Diabet Med,2008,25(2):152-156.
7Zinman B,Gerich J,Buse JB,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) [J].Diabetes Care,2009,32(7):1224-1230.
8Russell-Jones D,Vaag A,Schmitz O,et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU):a randomised controlled trial[J].Diabetologia,2009.52(10):2046-2055.
9DeFronzo RA,Ratner RE,Han J,Kim DD,Fineman MS,Baron AD.Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care,2005,28(5):1092-1100.
10Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD (liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,32(1):84-90.
